Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Analyses of c-Myc (MYC) and Topoisomerase II Alpha (TOP2A) Copy Number Aberrations; MYC, Insulin-like Growth Factor Receptor-1 (IGF-1R) and PTEN Protein Expressions; and Phosphatidylinositol 3' Kinase (PIK3) Gene Mutations in N9831 Primary Breast Tumors

NCT00898898 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT00898898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00898898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Analyses of c-Myc (MYC) and Topoisomerase II Alpha (TOP2A) Copy Number Aberrations; MYC, Insulin-like Growth Factor Receptor-1 (IGF-1R) and PTEN Protein Expressions; and Phosphatidylinositol 3' Kinase (PIK3) Gene Mutations in N9831 Primary Breast Tumors
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Observational
Overall status
Completed
Start date
May 31, 2000
Completion date
April 30, 2019
Enrollment
2,837 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer